Genomics, microbiomics, proteomics, and metabolomics in bronchopulmonary dysplasia

Semin Perinatol. 2018 Nov;42(7):425-431. doi: 10.1053/j.semperi.2018.09.004. Epub 2018 Oct 2.


Bronchopulmonary Dysplasia (BPD) is a disorder with a multifactorial etiology and highly variable clinical phenotype. Several traditional biomarkers have been identified, but due to the complex disease phenotype, these biomarkers have low predictive accuracy for BPD. In recent years, newer technologies have facilitated the in-depth and unbiased analysis of 'big data' in delineating the diagnosis, pathogenesis, and mechanisms of diseases. Novel systems-biology based 'omic' approaches, including but not limited to genomics, microbiomics, proteomics, and metabolomics may help define the multiple cellular and humoral interactions that regulate normal as well as abnormal lung development and response to injury that are the hallmarks of BPD.

Keywords: BPD; Genetics; Metabolome; Microbiome; Proteome; Systems biology.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Biomarkers / blood
  • Bronchopulmonary Dysplasia / blood
  • Bronchopulmonary Dysplasia / pathology*
  • Bronchopulmonary Dysplasia / physiopathology
  • Female
  • Genomics*
  • Humans
  • Infant, Newborn
  • Intercellular Signaling Peptides and Proteins / physiology
  • Lung / pathology*
  • Lung / physiology
  • Metabolomics*
  • Neonatology* / trends
  • Predictive Value of Tests
  • Pregnancy
  • Proteomics*
  • Respiratory Mucosa / metabolism*
  • Respiratory Mucosa / physiopathology


  • Biomarkers
  • Intercellular Signaling Peptides and Proteins